Examining Neuregulin and EGF Signaling in the Human Heart

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study investigates the role of the epidermal growth factor (EGF) receptor family and its ligands, particularly Neuregulin-1β (NRG), in regulating non-myocyte cells isolated from the human heart. It focuses on progenitor cells in the adult heart that respond to EGF and NRG, which are crucial for cardiac development and maintenance. Participants scheduled for heart surgery will provide small biopsies, which will be analyzed in the laboratory using flow cytometry and cell culture techniques to understand the biological regulation by these signaling pathways.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Clinical diagnosis of severe coronary artery disease scheduled to undergo coronary artery bypass surgery.

Exclusion Criteria:

* less than 18 years of age
* unwilling or unable to provide informed consent
* known active myocarditis
* hypertrophic cardiomyopathy
* constrictive pericarditis or other significant pericardial disease
* severe pulmonary hypertension
* significant renal impairment (Cr \> 2.5 mg/dL)
* severe ventricular arrhythmias
* pregnancy

Where it's running

• Maine Medical Center
  Portland, Maine, United States Recruiting

Study contacts

• Study coordinator: Joanne Burgess, RN
• Email: burgejs@mmc.org

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using the Supira percutaneous ventricular assist device during and after high-risk PCI

  This study will try the Supira percutaneous ventricular assist device to give extra heart support during and after high-risk PCI for patients with heart failure and reduced ejection fraction.

  Recruiting at 2 sites Supira Medical · Tbilisi, K'alak'i T'bilisi and 1 other locations · NCT07407816

• Using Apple Watch data to predict heart failure outcomes

  This study is testing if data from Apple Watches can help predict heart failure problems and the chances of needing to go back to the hospital for patients with heart failure.

  Recruiting University Medical Center Goettingen · Goettigen, Lower Saxony · NCT06819618

• Using AI and mobile technology to screen for dilated cardiomyopathy in family members

  This study is testing if using a special mobile EKG device can help family members of people with dilated cardiomyopathy get screened for heart problems more often.

  Recruiting Lancaster General Hospital · Lancaster, Pennsylvania · NCT06688396

• Comparing Aortix Device to Diuretics for Acute Heart Failure

  This study is testing whether the Aortix device can help people with acute heart failure who aren't responding to diuretics feel better compared to standard treatment.

  Recruiting at 33 sites Procyrion · Phoenix, Arizona and 49 other locations · NCT05677100

• Myocardial Energetics Across Cardiovascular Disease Spectrum Using 31P-MRS

  Researchers are testing whether phosphorus-31 magnetic resonance spectroscopy (31P-MRS) can map heart energy metabolism across healthy people and patients with various heart conditions.

  Recruiting Chinese Academy of Medical Sciences, Fuwai Hospital · Beijing · NCT07912086

• Differentiating heart disease in autoimmune vs. type 2 diabetes

  This study tests whether adult-onset autoimmune diabetes (AID/LADA) and type 2 diabetes (T2D) differ in how diabetic heart disease develops, using advanced heart imaging in people with AID, T2D, and healthy controls.

  Recruiting University of Roma La Sapienza · Rome, Roma · NCT07911007

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.